LOBEF.US Lobe Sciences Ltd

Healthcare Pharmaceuticals USA Stocks
0.0320 USD
Close of Nov 15, 2026
0.0021 0.0940
Market cap
USD 9.86M
P/E
-
P/B
7.45x
ROE
-271.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.

Is LOBEF.US undervalued?

Graham number

The Graham number of Lobe Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lobe Sciences Ltd fundamental analysis

No fundamental analysis for Lobe Sciences Ltd yet.

Lobe Sciences Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lobe Sciences Ltd

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.

Full company profile